Invitation to Alligator Bioscience’s earnings call on 5 May 2026

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its interim report for the period 1 January – 31 March 2026 on Thursday, 5 May 2026, at 8:00 a.m. CEST.

On the same day, Alligator will host a webinar and conference call for investors, analysts, and media at 1:00 p.m. CEST / 7:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session.

The call will be held in English. Attendees are required to register via >>this link<< and are welcome to submit questions in advance to ir@alligatorbioscience.com.

The full report will be available upon publication on Alligator’s website.

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Categorized as